Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
Other equities analysts also recently issued research reports about the stock. Canaccord Genuity restated a “buy” rating and set a $70.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, May 8th. Guggenheim assumed coverage on shares of Atara Biotherapeutics in a research report on Thursday, March 15th. They set a “neutral” rating for the company. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Tuesday, May 1st. JMP Securities downgraded shares of Atara Biotherapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 28th. Finally, William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, April 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $43.33.
Shares of Atara Biotherapeutics stock opened at $39.85 on Wednesday. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -9.96 and a beta of 2.61. Atara Biotherapeutics has a one year low of $12.65 and a one year high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($1.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.13). sell-side analysts expect that Atara Biotherapeutics will post -4.06 earnings per share for the current year.
In related news, EVP Mitchall G. Clark sold 4,647 shares of the stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $46.06, for a total value of $214,040.82. Following the sale, the executive vice president now directly owns 357,905 shares of the company’s stock, valued at approximately $16,485,104.30. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Mitchall G. Clark sold 22,400 shares of the stock in a transaction dated Thursday, March 29th. The shares were sold at an average price of $40.07, for a total transaction of $897,568.00. The disclosure for this sale can be found here. Insiders sold a total of 125,444 shares of company stock valued at $5,649,134 in the last quarter. Insiders own 10.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Riverhead Capital Management LLC acquired a new stake in Atara Biotherapeutics in the 1st quarter valued at about $100,000. SG Americas Securities LLC acquired a new stake in Atara Biotherapeutics in the 1st quarter valued at about $107,000. Principal Financial Group Inc. acquired a new stake in Atara Biotherapeutics in the 1st quarter valued at about $214,000. Teacher Retirement System of Texas acquired a new stake in Atara Biotherapeutics in the 1st quarter valued at about $260,000. Finally, Wasatch Advisors Inc. acquired a new stake in Atara Biotherapeutics in the 1st quarter valued at about $395,000. 98.37% of the stock is currently owned by hedge funds and other institutional investors.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.